Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

NCT03208296 is registered in ClinicalTrials.gov with Ascend Biopharmaceuticals Ltd as lead sponsor.

NCT NCT03208296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03208296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
Lead sponsor
Ascend Biopharmaceuticals Ltd
Phase
Phase 1/2
Overall status
Suspended
Start date
December 1, 2017
Completion date
March 31, 2025
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma in basal cell nevus syndrome